Contemporary Management and Prognosis in Japanese peripheral artery disease patients with endovascular treatment

Contemporary Management and Prognosis in Japanese peripheral artery disease patients with endovascular treatment - TOMAcode Registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015100

Enrollment

2000

Registered

2014-09-09

Start date

2014-09-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral artery disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.patients with endovasculartreatment in the lower limb 2.patients with agreement for study

Exclusion criteria

Exclusion criteria: 1.patients with endovascular treatment for the aneurysm 2.inappro@riate patients determined from study director

Design outcomes

Primary

Measure	Time frame
Patients Base: MACCE;Major Adverse Cardio-CerebroVascular Event(all cause death, myocardial infarction,stroke) MAE;Major Adverse Event(MACCE,unscheduled major amptation, acute limb ischemia, major limb reintervention) Limb base: MALE;Major Adverse Limb Event(unscheduled major amptation, unscheduled major limb reintervention, acute limb ischemia, unscheduled limb endovascular treatment)	—

Secondary

Measure	Time frame
1.safty in endovascular treatment 2.Procedure and lesion success 3.Puncture site complications by hemostasis device use 4.limb reintervention with restenosis 5.limb endovascular treatment with new lesion 6.stent thrombosis in lower limb 7.Bleeding event 8.Aortic event 9.event that requires regular hemodialysis 10.hospitalization with heart failure 11.new diagonosis of malignancy 12.change of limb sympton	—

Measure

Time frame

1.safty in endovascular treatment 2.Procedure and lesion success 3.Puncture site complications by hemostasis device use 4.limb reintervention with restenosis 5.limb endovascular treatment with new lesion 6.stent thrombosis in lower limb 7.Bleeding event 8.Aortic event 9.event that requires regular hemodialysis 10.hospitalization with heart failure 11.new diagonosis of malignancy 12.change of limb sympton

—

Countries

Japan

Contacts

Public ContactClinical Trials Support Office

Sakakibara Heart Institute Clinical Trials Support Office

tikenjim@shi.heart.or.jp042-314-3111

Outcome results